Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbro Linderholm

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Cancer Treatment and Research Communications|April 9, 2023
Compliance to adjuvant endocrine therapy and survival in breast cancer patientsChaido Chamalidou, Salmir Nasic, Barbro Linderholm
Methods in Molecular Medicine|February 24, 2006
Sequencing of the tumor suppressor gene TP 53Barbro Linderholm, Torbjörn Norberg, Jonas Bergh
Acta Oncologica (Stockholm, Sweden)|November 16, 2020
Delta NT-proBNP predicts cardiotoxicity in HER2-positive breast cancer patients treated with trastuzumabAnton E Andersson, Barbro Linderholm, Daniel Giglio
Applied Immunohistochemistry & Molecular Morphology : AIMM|May 28, 2004
HER-2/neu (c-erbB-2) evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ componentsJenny Andersson, Barbro Linderholm, Jonas Bergh, et al.
The International Journal of Biochemistry & Cell Biology|May 21, 2014
Molecular profiling of male breast cancer - lost in translation?Ida Johansson, Fredrika Killander, Barbro Linderholm, et al.
Breast (Edinburgh, Scotland)|September 5, 2024
Metronomic chemotherapy using capecitabine and cyclophosphamide in metastatic breast cancer - efficacy, tolerability and quality of life results from the phase II METRO trialKarolina Larsson, Jamila Adra, Leif Klint, et al.
Breast Cancer Research and Treatment|July 22, 2025
Changes in HER2low and HER2-ultralow status in 47 advanced breast carcinoma core biopsies, matching surgical specimens, and their distant metastases assessed by conventional light microscopy, digital pathology, and artificial intelligenceAnikó Kovács, Leif Klint, Barbro Linderholm, et al.
JCO Global Oncology|September 7, 2021
Breaking Bad News in Cancer Care: Ethiopian Patients Want More Information Than What Family and the Public Want Them to HaveAynalem Abraha Woldemariam, Rune Andersson, Christian Munthe, et al.
Molecular Cancer Research : MCR|October 17, 2008
An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cellsReidun Aesoy, Betzabe Chavez Sanchez, Jens Henrik Norum, et al.
Breast Cancer Research and Treatment|January 2, 2004
Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancerLisa Rydén, Barbro Linderholm, Niels Hilmer Nielsen, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Cancer Treatment and Research Communications|April 9, 2023
Compliance to adjuvant endocrine therapy and survival in breast cancer patientsChaido Chamalidou, Salmir Nasic, Barbro Linderholm
Methods in Molecular Medicine|February 24, 2006
Sequencing of the tumor suppressor gene TP 53Barbro Linderholm, Torbjörn Norberg, Jonas Bergh
Acta Oncologica (Stockholm, Sweden)|November 16, 2020
Delta NT-proBNP predicts cardiotoxicity in HER2-positive breast cancer patients treated with trastuzumabAnton E Andersson, Barbro Linderholm, Daniel Giglio
Applied Immunohistochemistry & Molecular Morphology : AIMM|May 28, 2004
HER-2/neu (c-erbB-2) evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ componentsJenny Andersson, Barbro Linderholm, Jonas Bergh, et al.
The International Journal of Biochemistry & Cell Biology|May 21, 2014
Molecular profiling of male breast cancer - lost in translation?Ida Johansson, Fredrika Killander, Barbro Linderholm, et al.
Breast (Edinburgh, Scotland)|September 5, 2024
Metronomic chemotherapy using capecitabine and cyclophosphamide in metastatic breast cancer - efficacy, tolerability and quality of life results from the phase II METRO trialKarolina Larsson, Jamila Adra, Leif Klint, et al.
Breast Cancer Research and Treatment|July 22, 2025
Changes in HER2low and HER2-ultralow status in 47 advanced breast carcinoma core biopsies, matching surgical specimens, and their distant metastases assessed by conventional light microscopy, digital pathology, and artificial intelligenceAnikó Kovács, Leif Klint, Barbro Linderholm, et al.
JCO Global Oncology|September 7, 2021
Breaking Bad News in Cancer Care: Ethiopian Patients Want More Information Than What Family and the Public Want Them to HaveAynalem Abraha Woldemariam, Rune Andersson, Christian Munthe, et al.
Molecular Cancer Research : MCR|October 17, 2008
An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cellsReidun Aesoy, Betzabe Chavez Sanchez, Jens Henrik Norum, et al.
Breast Cancer Research and Treatment|January 2, 2004
Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancerLisa Rydén, Barbro Linderholm, Niels Hilmer Nielsen, et al.
Pageof 5